Accolade Inc. Stock News

Accolade is in a good position to meet its revenue growth guidance for both the current fiscal year and long term. There is a risk that ACCD's bottom line could fall short of expectations in subsequen

SEATTLE, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will release fiscal second quarter 2024 finan

SEATTLE, Sept. 06, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Sept. 5, 2023 by Accolade, Inc. (NASDAQ: ACCD), please note that in the second bullet, the time of the Morgan

Cathie Wood bought shares of Palantir, Intellia Therapeutics, and Accolade on Thursday. Palantir was downgraded by a prominent analyst on Thursday, and it recently posted its weakest quarterly revenue

Ark Invest has continued to trim its holdings in Nvidia although it's still a large holder. Meanwhile, the investment firm has been increasing its bets in the biotech sector.

Accolade is experiencing strong demand due to rising healthcare costs and employers seeking ways to reduce expenses. The company's proprietary technology platform and health assistants provide persona

I maintain a buy rating for ACCD as I expect growth reacceleration in FY25 which will drive valuation upwards. ACCD's management has raised revenue expectations for FY24 and reiterated long-term reven

Accolade Inc. NASDAQ: ACCD is an artificial intelligence (AI) powered healthcare platform that provides personalized healthcare guidance for employers and workers. The platform helps people manage

The specialty healthcare solutions provider unveiled its latest set of quarterly results. These handily beat analyst estimates on both the top and bottom lines.

Accolade, Inc. (NASDAQ:ACCD ) Q1 2024 Earnings Conference Call June 29, 2023 4:30 PM ET Company Participants Todd Friedman - SVP, IR Rajeev Singh - CEO Steve Barnes - CFO Shantanu Nundy - Chief Health

Accolade (ACCD) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.40 per share a year ago.

SEATTLE, June 13, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will release fiscal first quarter 2024 financi

SEATTLE, June 01, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will be presenting at the Stifel 2023 Cross Se

ACCD has experienced high demand, with revenue increasing by 5.6% in 4Q23 and a 33% increase in ARR bookings. During the analyst day, ACCD upgraded its FY25 margin target and expressed confidence in r

On May 23, 2023, Stephen Barnes, the Chief Financial Officer (CFO) of Accolade Inc ( ACCD , Financial), sold 631 shares of the company. This article will provide an overview of Stephen Barnes, Accolad